Navigation Links
Conference on cell therapy includes new session on stem cells for non-cardiac organ injury
Date:1/5/2009

WHAT:

The Fifth International Conference on Cell Therapy for Cardiovascular Disease (IC3D) will include a new session on stem cells for non-cardiac organ injury. The session will include new data on stem cells for islet disease and diabetes, bone marrow cells for stroke patients, and treating Parkinson's disease with bone marrow cells.

Highlights from other sessions include the first human data using special bone marrow and adipose cells for heart attack patients and a discussion of the rapid advances in tissue engineering and how surgeons should prepare for this next stage of stem cell therapy.

WHY:

IC3D, one of the largest conferences of its kind with more than 60 internationally recognized faculty members, is a three-day comprehensive program dedicated to the evolving field of cell-based therapies for cardiac repair and regeneration. The theme of this year's meeting is "Cellular and Molecular Building Blocks: Strategies for Cardiovascular Reconstruction in 2009."

The conference encompasses all aspects of cell-based therapeutic approaches to cardiovascular diseases. Research presented at IC3D will touch upon clinical studies of stem cell repair of the heart, brain and peripheral arteries, new sources of adult stem cells and the status of embryonic stem cell research. Each day of the conference will focus on the following diseases and the future role of cell-based therapies.

PROGRAM SPECIFICS:

New sessions for 2009 will include:

  • Major advances in treating peripheral vascular disease
  • Combined cell and tissue regenerative methods
  • Changing the potential of stem cells: Why should we try? How do we do it?
  • New paradigms for the surgeon? How soon will engineered tissue be in the clinic?
  • Discoveries beyond the heart, including the brain and other organs
  • Expanded sessions on Industry Innovations in 2009

The full agenda can be found at:
'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
2. Alexion to Present at the 27th Annual JP Morgan Healthcare Conference
3. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 13, 2009
5. WellPoint to Hold Conference Call and Webcast to Discuss Fourth Quarter Results on January 28, 2009
6. 40 Days for Life Leader to Speak at Personhood Conference
7. Delcath Systems to Host Quarterly Update Conference Call
8. Medco CEO to Present at the 2009 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Conference
9. Spending Too Much on Healthcare? This Employer-Designed Conference Will Inspire!
10. Hospira to Present at J.P. Morgans 27th Annual Healthcare Conference January 14
11. Abaxis, Inc. to Present at Needham & Companys Eleventh Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2009)...ent pain and injury, doctors say , , SAT...rs are not as young as they used to be, exercise i...ns are in order to stay injury-free. , "As b...t themselves from injuries when exercising," Dr. R...Orthopaedic Surgeons, said in a news release. "A l...
(Date:7/3/2009)...on in microbiology testing walks on four legs and ...e version of the familiar woolly barnyard resident...of Medicine, which is to be published July 3 in P...low-maintenance and parasite-resistant, they,re al... necessary to diagnose infectious disease in the d...
(Date:7/3/2009)...e/ -- Bertalan Mesko, medical blogger and health 2...dical professionals focusing on how the virtual wo...are expensive and patients are also open to use vi...ctors enter a virtual realm and organize medical p...provides opportunities for case presentations, e-l...
(Date:7/3/2009)...ll lead to treatments, , , FRIDAY, July...ve found a major cellular flaw that may drive the ...ught early, lung cancer can often be treated. But ...ell advanced. Though doctors can sometimes put the...back more virulent than ever, frequently spreading...
Breaking Medicine News(10 mins):Health News:Exercise Tips to Keep Boomers on Their Feet 2Health News:Rare sheep could be key to better diagnostic tests in developing world, says Stanford study 2Health News:Rare sheep could be key to better diagnostic tests in developing world, says Stanford study 3Health News:Cell Pathway May Be Key to Lung Cancer's Spread 2Health News:Cell Pathway May Be Key to Lung Cancer's Spread 3
...es home from a stressful day at work and hoes in h...ing positive mental and emotional results// from t...rticultural therapy,” Airhart explained. “Horticu...ith measurable objectives and outcomes that are cl...
...conducted by Dr. David Schutt of Thomson Medstat, ...found that more than three-quarters// of Americans...hy. About 11,000 people were contacted by phone a...igorous exercise for times a week. About 28% of th...
...ssible outbreak of a highly infectious strain of a...d in the latest issue// of the Medical Journal of ...ile) is the most commonly diagnosed cause of infec...rrhoea in developed countries, including Australia...
...colate bars and ice cream wrappers contain latex a...ons in people who are already sensitive// and that...t was reported that the study had been commissione...nd was conducted by Leatherhead Food International...
Other Medicine News:Health News:Horticultural Therapy Offers Measurable Physical, Mental Benefits 2Health News:Horticultural Therapy Offers Measurable Physical, Mental Benefits 3Health News:Horticultural Therapy Offers Measurable Physical, Mental Benefits 4Health News:New Diarrhoea Bug Warning in Australia 2Health News:Study Finds That Food Wrappers Could Be A Source For Health Risks 2
(Date:6/30/2009)...une 30 Accumetrics, Inc. announces...nts) in the enrollment of its landmark clinical tr...V erifyNow(R) Assay I mpact on T hrombosis A nd... demonstrate the value of providing clinicians wit... responders to clopidogrel (Plavix(R)). The multi...
(Date:6/30/2009)...M, The Netherlands, June 30 , ...n-Making Process With,Respect to Infertility Trea... presented today at this year,s,European Society ...ess showed,that, within the parameters of the sim...VF) treatment MENOPUR (highly-purified human menop...
(Date:6/29/2009)...or abdominal surgery patients achieved primary and...June 29 AcelRx Pharmaceuticals, In...d Phase 2 clinical study evaluating the safety and...r the management of acute post-operative pain in p...ization. Compared to placebo, patients receiving A...
(Date:6/28/2009)...lif., June 29 Sangamo Bi...that a key research milestone has been achieved in..., Inc., a wholly-owned member of the Roche Group, ...teristics for pharmaceutical protein production pu...-binding protein nuclease (ZFN) technology. Genent...
Breaking Medicine Technology:Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 2New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 3New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 4AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Life Recovery Systems Study of Heart Attack With ThermoSuit 28R 29 System 14031 1Life Recovery Systems Study of Heart Attack With ThermoSuit 28R 29 System 14031 2Life Recovery Systems Study of Heart Attack With ThermoSuit 28R 29 System 14031 3Franklin 26 Seidelmann Publishes Complex Podiatry MRI Study 1501 1Franklin 26 Seidelmann Publishes Complex Podiatry MRI Study 1501 2Franklin 26 Seidelmann Publishes Complex Podiatry MRI Study 1501 3Paradigm shift 3A Switch for programmed cell death promotes spread of glioblastoma 14025 1Paradigm shift 3A Switch for programmed cell death promotes spread of glioblastoma 14025 2Royal corruption is rife in the ant world 2462 1Royal corruption is rife in the ant world 2462 2
... and NUTLEY, N.J., April 23, 2007 /PRNewswire/ --,...if a renal anemia,treatment administered once ever... of epoetin alfa, hemodialysis centers may save an... per year per 100,patients. These data, from a mul...t in hemodialysis patients, were presented today,d...
...olo., April 24, 2007 /PRNewswire/ -- Accera Inc.,a...b study of its,lead compound AC-1202 in Alzheimer,...ting of the American Academy of Neurology (AAN) in...ercent of the,program, the data will also be featu..., Accera,s vice president of clinical development ...
Other Medicine Technology:Prospective Model Outlined Potential Time and Cost Savings of,Once-Monthly Anemia Treatment 2Prospective Model Outlined Potential Time and Cost Savings of,Once-Monthly Anemia Treatment 3Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting 2
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications.
Unipolar temporary atrial pacing lead is smaller and thinner than Medtronics standard temporary pacing leads. It is well suited for thin, delicate, atrial tissue.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
Medicine Products: